Astellas Pays US$300 M Upfront to Access Immunomic’s LAMP-vax™ Platform
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2015 Issue 10 (Table of Contents)
Published: 24 Oct-2015
DOI: 10.3833/pdr.v2015.i10.2128 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In line with its aim of developing a global vaccines franchise, Astellas Pharma has established a second alliance with Immunomic Therapeutics, this time gaining exclusive access to the company’s LAMP-vax™ (lysosomal-associated membrane protein vaccine) technology platform in the field of human allergic diseases in return for US$300 M upfront plus a 10% royalty rate...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS